Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

1999-03-03

Study Completion Date

2001-10-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol is designed to evaluate the side effects of rV-DF3/MUC1 and to determine the safest dose which should be used in the treatment of breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

NCT00071942

Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer

TERMINATED PHASE1

Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer

NCT00706615

Breast Cancer

WITHDRAWN PHASE1

Vaccine Therapy in Treating Patients With Breast Cancer

NCT00004156

Breast Cancer

COMPLETED PHASE1

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

NCT00048893

Breast Neoplasms Metastases, Neoplasm

TERMINATED PHASE1/PHASE2

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

NCT00030693

Unspecified Adult Solid Tumor, Protocol Specific

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES: I. Determine the toxicity associated with repeated vaccination with recombinant vaccinia DF3/MUC1 vaccine (rV-DF3/MUC1) in patients with metastatic breast cancer. II. Determine the maximum tolerated dose of rV-DF3/MUC1, based on cellular and humoral immunity, in these patients. III. Determine whether vaccination with rV-DF3/MUC1 is associated with antitumor activity in these patients.

OUTLINE: This is an open label, dose escalation study. Patients receive recombinant vaccinia DF3/MUC1 vaccine (rV-DF3/MUC1) intradermally. Treatment repeats every month for 3 courses in the absence of disease progression or unacceptable toxicity. Cohorts of at least 6 patients receive escalating doses of rV-DF3/MUC1 until the maximum tolerated dose (MTD) or the highest dose level to be tested is reached. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Patients are followed monthly for 6 months.

PROJECTED ACCRUAL: A total of 16-28 patients will be accrued for this study within 1-2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

rV-DF3/MUC1

* rV-DF3/MUC1 vaccinations will be administered 4 week intervals for a total of 3 doses.
* Participants will be followed weekly until 28 days after the final dose (day 85) then month for 6 months

Group Type EXPERIMENTAL

rV-DF3/MUC1

Intervention Type BIOLOGICAL

\- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.

\-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination

* Level 1 4.76 x 106 PFU
* Level 2 4.76 x 107 PFU
* Level 3 4.76 x 108 PFU

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rV-DF3/MUC1

\- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.

\-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination

* Level 1 4.76 x 106 PFU
* Level 2 4.76 x 107 PFU
* Level 3 4.76 x 108 PFU

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a histologically confirmed diagnosis of metastatic adenocarcinoma of the breast. Patients may have measurable disease, but it is not required. Patients may have received any number of prior therapies for metastatic disease. Untreated patients are also eligible.
* Age ≥ 18 years
* Patients must have an ECOG = Performance Status of 0-1
* Patients must have a WBC \> 2000/mm 3 and a platelet count \> 100,000/mm3.
* Patients must have adequate renal function documented by a serum creatinine \< 2.0 mg/d1.
* Patients must have adequate liver function demonstrated by a serum bilirubin \< 2.0 mg/di, and a SGPT \< 4 times the upper limit of normal.
* ≥3 weeks since chemotherapy (\> 6 weeks for nitosoureas or mitomycin C), hormonal therapy or radiation therapy
* Immunologic testing must be at least normal as defined by at least normal delayed type hypersensitivity, at least normal CD4: CD8 ratio (\>1), at least normal lymphocyte proliferation testing (to Con A), and at least normal immunoglobulin levels
* Patients must not have evidence of altered immune responsiveness or autoimmune syndromes (scleroderma,systemic lupus erythematosus, etc.). Patients must be HIV negative. This treatment may be associated with increased adverse effects for individuals with immune deficiencies, and HIV-associated symptoms preclude accurate assessment of toxicity.
* Patients must not have undergone splenectomy.
* Patients with active cases or history of extensive skin disorders (such as extensive psoriasis, burns, impetigo, disseminated zoster) are ineligible.
* Patients must not have any other serious medical condition which in the opinion of the investigator is incompatible with the protocol. Patients with active infections requiring antibiotics are not eligible until the infection has cleared and the antibiotics have been stopped for at least 3 days.
* Patients must be able to avoid close contact with children \< 3 years of age, pregnant women, individuals with eczema or skin conditions and immune suppressed individuals during a period of two weeks after each vaccination.
* Patients must have had prior vaccinia (small pox) exposure.
* Tumor tissue positive for staining with MAbs DF3 and/or DF3-P or elevated serum CA15-3. Note: This can be done on stored slides.
* Patients must not have a history of seizures, encephalitis or multiple sclerosis.
* Patients must not be allergic to eggs.
* Patients must not be pregnant or breast-feeding due to a possible increased risk with exposure to vaccinia virus of both mother and newborn as well as unknown risks to the fetus.
* Signed informed consent.

Exclusion Criteria

* Patients must not have evidence of altered immune responsiveness or autoimmune syndromes (scleroderma, systemic lupus erythematosus, etc.). Patients must be HIV negative This treatment may be associated with increased adverse effects for individuals with immune deficiencies, and HIV-associated symptoms preclude accurate assessment of toxicity.
* Patients must not have undergone splenectomy
* Patients with active cases or history of extensive skin disorders (such as extensive psoriasis, burns, impetigo, disseminated zoster) are ineligible.
* Patients must not have any other serious medical condition which in the opinion of the investigator is incompatible with the protocol. Patients with active infections requiring antibiotics are not eligible until the infection has cleared and the antibiotics have been stopped for at least 3 days.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No